Catalent Solidifies Inhalation Product Development Capabilities With New Offering
on: January 12, 2010, 3:31 am
Jennings and Co.
Catalent Pharma Solutions has acquired advanced fine powder
filling capability, which solidifies Catalent’s position as a leader in
development and manufacturing services to the pharmaceutical inhalation
sector. With the purchase of Harro Höfliger’s Omnidose filling
equipment, Catalent now offers its customers fully scaleable dry powder
inhaler (DPI) filling capability. This widely-accepted technology, to
be housed in Catalent’s Research Triangle Park, North Carolina
facility, provides a flexible platform to reliably support all clinical
manufacture through Phase II/III and a scaleable path to higher volume
late stage clinical and commercial manufacturing.
The Harro Höfliger equipment is an advanced technology specialized in powder filling
for microdosing, in the 1 – 300 mg of powder range, into an array of DPI formats to
include both capsule-based and pre-metered blister device formats. This new
capability gives Catalent a full range of pulmonary and nasal services, filling a
gap in the marketplace for advanced powder filling capabilities. Catalent will now
be able to serve as a one-stop-shop for the development of all inhalation dosage
forms, possessing both the capital assets and technical experience. This recent
addition complements Catalent’s pre-existing automated pMDI infrastructure.
Catalent’s primary location for inhalation product development is in Research
Triangle Park, North Carolina where its experienced team offers comprehensive
pulmonary and nasal services to help take a product from concept through regulatory
approval. Catalent has extensive experience with all pulmonary dosage forms
including pMDIs, DPIs, nasal sprays and solutions/suspensions for inhalation. For
more information on Catalent’s proficiency in dosage form selection, technology
assessment, formulation development, analytical testing and supplying toxicological
and clinical trial materials, please visit www.catalent.com/development.
Headquartered in Somerset, New Jersey, Catalent is one of the leading providers of
advanced dose form and packaging technologies, and development, manufacturing, and
packaging services for pharmaceutical, biotechnology and consumer healthcare
companies in nearly 100 countries. Catalent applies its local market expertise and
technical creativity to advance treatments, change markets and enhance patient
outcomes. Catalent employs approximately 9,500 at 30 facilities worldwide and in
fiscal 2009 generated more than $1.6 billion of annual revenue. For more
information, visit www.catalent.com.
Contact Details: Patricia A. McGee
(732) 537 6407
Dan Dunlop, Jennings
Peggy Albertson, Jennings